ConductScience.org, home

Comparison · NCT00955487-682bbac7

Inhaled Nitric Oxide (iNO) vs Placebo (Nitrogen): Severe Intracranial Hemorrhage

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Inhaled Nitric Oxide (iNO) vs Placebo (Nitrogen): Severe Intracranial Hemorrhage. Trial comparisons, record NCT00955487-682bbac7. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00955487-682bbac7

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.03390.009350.115wilson
Risk in group 20.06150.02420.148wilson
Risk difference, group 1 minus group 2-0.0276-0.1170.062newcombe hybrid score
Risk ratio, group 1 over group 20.5510.1052.9log
Odds ratio, group 1 over group 20.5350.09443.03log
Number needed to treat, for one fewer participant with the outcome on Inhaled Nitric Oxide (iNO) than on Placebo (Nitrogen)36.2from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Inhaled Nitric Oxide (iNO)
Participants will receive a low concentration of iNO until they are 30 weeks corrected gestational age or for 14 days if they were born at 29 weeks or more.~Inhaled Nitric Oxide (iNO) will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
259OG000
Group 2Placebo (Nitrogen)
Participants will receive Placebo until they are 30 weeks corrected gestational age or for 14 days if they were born at 29 weeks or more.~Placebo will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
465OG001

Outcome

Type
SECONDARY
Title
Severe Intracranial Hemorrhage
Description
Number of participants that developed severe intracranial hemorrhage (grade 3-4)
Time frame
Randomization to discharge
Population

Source ClinicalTrials.gov

Trial

Title
Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns
NCT number
NCT00955487
Phases
PHASE2
Conditions
Bronchopulmonary Dysplasia
Interventions
Inhaled Nitric Oxide (iNO), Nitrogen (placebo)
Lead sponsor
University of Colorado, Denver
Results first posted
2017-05-23

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00955487-682bbac7